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OBJECTIVE—O-linked -N-acetylglucosamine (O-GlcNAc) plays
an important role in the development of insulin resistance and
glucose toxicity. O-GlcNAcylation is regulated by O-GlcNAc trans-
ferase (OGT), which attaches O-GlcNAc to serine and/or threonine
residues of proteins and by O-GlcNAcase, which removes O-Glc-
NAc. We investigated the expression of these two enzymes in
erythrocytes of human subjects with diabetes or pre-diabetes.
RESEARCH DESIGN AND METHODS—Volunteers with nor-
mal condition, pre-diabetes, and diabetes were recruited through a
National Institutes of Health (National Institute of Diabetes and
Digestive and Kidney Diseases) study and at the Johns Hopkins
Comprehensive Diabetes Center. Erythrocyte proteins were ex-
tracted and hemoglobins were depleted. Global O-GlcNAcylation of
erythrocyte proteins was conﬁrmed by Western blotting using an
O-GlcNAc–speciﬁc antibody. Relative OGT and O-GlcNAcase pro-
tein amounts were determined by Western blot analysis. Relative
expression of O-GlcNAcase was compared with the level of A1C.
RESULTS—Erythrocyte proteins are highly O-GlcNAcylated.
O-GlcNAcase expression is signiﬁcantly increased in erythro-
cytes from both individuals with pre-diabetes and diabetes
compared with normal control subjects. Unlike O-GlcNAcase,
protein levels of OGT did not show signiﬁcant changes.
CONCLUSIONS—O-GlcNAcase expression is increased in
erythrocytes from both individuals with pre-diabetes and individ-
uals with less well-controlled diabetes. These ﬁndings, together
with the previous study that demonstrated the increased site-
speciﬁc O-GlcNAcylation of certain erythrocyte proteins, suggest
that the upregulation of O-GlcNAcase might be an adaptive
response to hyperglycemia-induced increases in O-GlcNAcyla-
tion, which are likely deleterious to erythrocyte functions. In any
case, the early and substantial upregulation of O-GlcNAcase in
individuals with pre-diabetes may eventually have diagnostic
utility. Diabetes 59:1845–1850, 2010
O
-GlcNAcylation is a posttranslational modiﬁca-
tion in which single O-linked N-acetylglu-
cosamine (O-GlcNAc) residues are attached to
the hydroxyl groups of serine and/or threonine
moieties of proteins within the nucleus and cytoplasm.
O-GlcNAcylation is an abundant, inducible, and reversible
modiﬁcation. O-GlcNAc serves as a nutrient/stress sensor
to modulate signaling, transcription, proteasomal activity,
cytoskeletal assemblies, and cellular activities (for re-
views, [1,2]). Recent studies have established that the
dynamic crosstalk between O-GlcNAcylation and phos-
phorylation is extensive (3,4).
Unlike phosphorylation, O-GlcNAcylation is regulated
by only two known enzymes, uridine diphospho-N-acetyl-
glucosamine:polypeptide -N-acetylglucosaminyltransferase
(O-GlcNAc transferase [OGT]) (5,6), which transfers
O-GlcNAc from UDP-GlcNAc (uridine diphospho-N-
acethylglucosamine) to proteins, and O-linked -N-ace
tylglucosaminidase (O-GlcNAcase [OGA]) (7), which re-
moves O-GlcNAc from proteins. However, both enzymes
have many transient binding partners within cells, thus
creating many different holoenzyme complexes presumably
with different speciﬁcities and expression patterns. OGT is
essential for life in mammals at the single-cell level (8).
Over-expression of OGT in muscle or adipose tissue of mice
causes hyperleptinemia and insulin resistance (9).
O-GlcNAcase, a nucleocytoplasmic -N-acetylglucosamini-
dase, is distinct from lysosomal hexosaminidases (7,10). The
O-GlcNAcase gene was found to be identical to meningio-
ma-expressed antigen 5 (MGEA5) (11). O-GlcNAcase also
plays a role in mediating insulin signaling and insulin
resistance. Competitive inhibition of O-GlcNAcase using
O-(2-acetoamido-2 deoxy-D-glucopyranosylidene)-amino-
N-phenylcaramate (PUGNAc, Ki  54 nmol/l) results in
decreased glucose uptake in response to insulin in adipo-
cytes, termed insulin resistance, the hallmark of type 2
diabetes (12). A single mutation in the O-GlcNAcase gene
(MEGA5 gene) results in higher susceptibility to diabetes
in a Mexican American population (13). This mutation
causes an early termination of translation of O-GlcNAcase
and leads to a decrease in the expression of active
O-GlcNAcase, suggesting that mutations in O-GlcNAcase
may be a risk factor for type 2 diabetes in certain popula-
tions but not in others.
One of the earliest studies of O-GlcNAc was performed in
human erythrocytes (14). However, the role of O-GlcNAcy-
lation in erythrocytes is still unknown. Recent proteomic
studies have revealed that erythrocytes have a complex
cellular system to regulate their physiology (15–17).
Herein, we examined the protein levels of OGT and
O-GlcNAcase, as well as O-GlcNAcylation in human eryth-
rocytes from subjects with normal, pre-diabetic, and dia-
betic conditions.
RESEARCH DESIGN AND METHODS
Human blood samples were collected from two sources of volunteers. One set
was obtained through the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) and clinical data are shown in the supplemental
material (available in the online appendix at http://diabetes.diabetesjournals.
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Hopkins Comprehensive Diabetes Center (JH Center). Clinical data collected
in this pilot phase was restricted to age, body weight, a causal plasma glucose,
and A1C. In JH Center subjects, the diagnosis of diabetes had been established
by accepted clinical criteria for 1 year with documented hyperglycemia and
elevated A1C. Subjects designated as normal had no personal history suggest-
ing diabetes. Blood samples were drawn and separated. Erythrocytes were
washed with cold PBS three times and stored at 80°C. JH Center samples
were obtained by the same procedure except using Histopaque-1077 (Sigma-
Aldrich) reagent according to the manufacturer’s protocol. Subjects gave
written consent, which was approved by the applicable institutional review
boards.
Hemoglobin depletion. Erythrocytes were lysed in NP40 lysis buffer (PBS,
0.5% NP-40, protease inhibitors). Samples were brieﬂy sonicated and centri-
fuged for 10 min at 13,000 rpm at 4°C. Lysate was recovered and hemoglobins
were depleted using HemogloBind Resin (Biotech Support Group) according
to the manufacturer’s protocol. The depletion process was repeated twice to
remove up to 90% of hemoglobin.
Western blot analysis. Hemoglobin-depleted lysate was subjected to SDS-
PAGE gels and blotted to polyvinylidene ﬂuoride membranes. Membranes
were blocked in Tris-buffered saline with Tween (0.1% [v/v] Tween-20) with
either 3% (weight/volume) BSA or 5% (weight/volume) nonfat milk and
incubated overnight at 4°C with the appropriate primary antibodies O-GlcNAc
(CTD110.6) (Covance), OGT (AL28), O-GlcNAcase (18), actin (Sigma), and
glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology). De-
tection was performed by enhanced chemiluminescence.
Expression and puriﬁcation of recombinant O-GlcNAcase. Human O-
GlcNAcase cDNA was subcloned. Protein expression and puriﬁcation proce-
dure was carried out as previously described (18).
Statistical analysis. Densitometry data were obtained by the ImageJ pro-
gram (National Institutes of Health), and analysis was performed using
Student t test. P value 0.05 (two-tailed) was considered signiﬁcant. Data are
presented as means  SEM.
RESULTS
The characteristics of the subjects are summarized in
Table 1 and the supplemental table. The JH Center cohort
was selected to be more hyperglycemic than the NIDDK
group. The differences in pathogenesis between type 1 and
type 2 diabetes were not considered important for this
study since both cause chronic hyperglycemia, which
affects O-GlcNAcylation.
Erythrocytes have many GlcNAcylated proteins. One
of the earliest studies of O-GlcNAc showed the presence of
O-GlcNAcylated proteins in human erythrocytes (14), and
our recent study showed that the site-speciﬁc O-GlcNAcy-
lation of certain erythrocyte proteins increases in individ-
uals with diabetes (19). The supplemental ﬁgure shows
examples illustrating O-GlcNAcylation on many human
erythrocyte proteins.
Expression of O-GlcNAcase increases in erythrocytes
from both individuals with pre-diabetes and diabetes.
O-GlcNAcase protein expression was determined by
Western blot and analyzed by densitometry. O-GlcNA-
case protein levels increased in individuals with pre-
diabetes and diabetes by 1.25- and 1.5-fold, respectively
(**P  0.01) (Fig. 1A and B). The difference in O-
GlcNAcase levels between normal and diabetes was
even more pronounced in JH Center samples, which
were selected to have higher differences in blood glu-
cose levels and were found to be consistently 2.0–2.5-
fold increased (Fig. 1C and D). We attempted to
examine the enzymatic activity of O-GlcNAcase from
both sample sets, however, due to the liability of
O-GlcNAcase to freezing (20), such assays were not
reliable.
Measurement of O-GlcNAcase in erythrocytes. To
measure the amount of O-GlcNAcase protein in erythro-
cytes, we performed Western blot analyses using recom-
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FIG. 1. Elevation of protein levels of O-GlcNAcase in pre-diabetic and diabetic erythrocytes. Protein levels of O-GlcNAcase were determined by
Western blotting in NIDDK samples (A and B) and JH Center samples (C and D). A: Representative Western blot analysis showing that protein
levels of O-GlcNAcase are elevated twofold in the pre-diabetic (n  13, **P < 0.01) and diabetic samples (n  9, P < 0.01) compared with normal
samples (n  13). B: Quantitation of Western blot analysis (A). C: Representative Western blot analysis showing that protein levels of
O-GlcNAcase are elevated 2.5-fold in the diabetic (n  14, P < 0.01) compared with normal samples (n  8). D: Quantitation of Western blot
analysis (C). Actin was used as a loading control. E: Protein levels of O-GlcNAcase were estimated in JH Center samples by Western blotting with
recombinant O-GlcNAcase as standard. F: Quantitation based on Western blot analysis. Diabetic samples (18.70  5.91 ng/100 g of proteins, n 
10, *P < 0.05) have threefold more O-GlcNAcase than normal samples (6.10  1.93 ng/100 g of proteins, n  10). Data are means  SEM.
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samples had 6.1  1.93 ng and 18.7  5.91 ng of O-
GlcNAcase per 100 g of hemoglobin-depleted erythrocyte
proteins, respectively (*P  0.05) (Fig. 1E and F). Thus
diabetic erythrocyte samples had on average three-fold
more O-GlcNAcase than did normal samples.
Protein level of OGT does not change in diabetic
condition. Protein expression of OGT was also examined
in erythrocytes by Western blotting. OGT showed a slight
but statistically insigniﬁcant increase in pre-diabetic and
diabetic samples when compared with normal samples
(Fig. 2A and B). Similar results were observed in JH Center
samples (Fig. 2C and D). Thus while these data show that
human erythrocytes do contain both enzymes, only O-
GlcNAcase expression is upregulated in pre-diabetic and
diabetic erythrocytes.
Comparison of O-GlcNAcase and A1C. Since the ex-
pression of O-GlcNAcase increases in pre-diabetes prior to
elevation in A1C, we directly compared O-GlcNAcase
expression and A1C levels in the samples. A1C value was,
TABLE 1
Baseline characteristics of NIDDK and JH Center subjects. More detailed clinical information of NIDDK samples is provided in the
supplemental table in the online appendix.
NIDDK JH Center
Normal Pre-diabetes Type 2 diabetes Normal Diabetes
n 13 13 9 23 44
Age (years) 51.2  6.6 54.5  9.6 53.8  9.2 31  8.2 52.9  12.4
Sex (male/female) 2/11 3/10 4/5 11/12 21/23
Fasting glucose (mg/dl) 87.8  4.2 98.2  9.3 128.9  18.6 NA NA
2-h glucose (mg/dl) 81.0  11.4 166.0  11.7 228.6  28.8 NA NA
Causal glucose NA NA NA 83.1  17.9 154.2  74.1
A1C (%) 5.0  0.3 5.3  0.3 6.1  0.7 5.5  0.4 8.3  1.7
Duration of diabetes (years) — — NA — 15.4  13.9
Type of diabetes (type 1/type 2) — — — — 20/24
Data are means  SE. NA, not applicable.
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FIG. 2. Protein levels of OGT in pre-diabetic and diabetic samples. Protein levels of OGT were determined by Western blotting in NIDDK
samples (A and B) and JH Center samples (C and D). A: Representative Western blot analysis showing that protein levels of OGT did not
signiﬁcantly change in the pre-diabetic (n  13) and diabetic samples (n  9) compared with normal samples (n  13). B: Quantitation of
Western blot analysis (A). C: Representative Western blot analysis. Changes of protein levels of OGT were not signiﬁcantly different
between the normal (n  14) and diabetic (n  8) samples. D: Quantitation of Western blot analysis (C). Actin was used as a loading control.
Data are means  SEM.
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overt diabetes but unlike O-GlcNAcase, A1C was not
signiﬁcantly different between normal and pre-diabetic
samples (Fig. 3A and B). The level of O-GlcNAcase expres-
sion varied more widely in pre-diabetes than normal
(possibly reﬂecting more variable glycemia), and the mean
was signiﬁcantly higher in pre-diabetes. In the NIDDK
samples, the range of O-GlcNAcase expression in the
diabetic samples largely overlapped with the samples from
individuals with pre-diabetes. Similar patterns were found
in the JH Center samples (Fig. 3C and D), which were
selected to compare individuals with more severely hyper-
glycemic diabetes with normal control subjects. In these
comparisons, the range of O-GlcNAcase protein expres-
sion was comparable with the range seen for A1C. This
suggests that the severity of hyperglycemia and the result-
ing increased global O-GlcNAcylation are related to the
increased amount of O-GlcNAcase expression in the eryth-
rocytes, perhaps as an adaptive response to maintain
erythrocyte functionality.
DISCUSSION
Currently there are several criteria to diagnose diabetes with
the oral glucose tolerance test (OGTT) often considered the
gold standard. However, the OGTT is a challenge in clinical
practice because it requires overnight fasting and a 2-h test.
Another diagnostic test for diabetes that is simpler and
equally sensitive would be an important advance.
Pre-diabetes is deﬁned on the basis of the OGTT as a
condition with impaired fasting glucose and/or impaired
glucose tolerance. A1C is routinely used to assess
glycemic control (21) and has recently been recom-
mended by a group of experts (22) and an international
expert committee (23) as a relatively sensitive and
speciﬁc method and a criterion for the diagnosis of
diabetes. However, A1C is probably not as sensitive in
detecting pre-diabetes. Furthermore, Derr et al. (24)
showed that A1C does not signiﬁcantly reﬂect the
variance of glycemia, only the mean. This suggests the
limitations of the A1C assay since liability of glycemia is
a crucial factor in diabetic management and possibly in
avoiding diabetic complications (25). This supports the
interest in developing a new screening method that is
less subject to current limitations.
Unlike nonenzymatic chemical glycation of proteins,
O-GlcNAcylation is a speciﬁc and regulated enzymatic
process. Thus it could reﬂect ﬂuctuations in glycemia in
broader dynamic ranges. We hypothesized that hypergly-
cemia may cause elevated O-GlcNAcylation and/or alter-
ations of the protein levels of OGT and O-GlcNAcase in
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FIG. 3. Comparison of A1C and O-GlcNAcase. The ranges of O-GlcNAcase and A1C were visualized and compared in NIDDK samples (normal 
13, pre-diabetes  13, diabetes  9) (A and B) and JH Center samples (normal  10, diabetes  10) (C and D). A and C: The range of O-GlcNAcase.
B and D: The range of A1C values. *P < 0.05, **P < 0.01. Filled circle indicates the highest and the lowest value of each sample.
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diabetes.
We recently demonstrated striking site–speciﬁc in-
creases in O-GlcNAcylation on several erythrocyte pro-
teins in response to the diabetic state (22). Interestingly,
O-GlcNAcase expression levels increased signiﬁcantly in
subjects with pre-diabetes and diabetes (Fig. 1). More
pronounced increases in O-GlcNAcase expression were
observed in the JH Center samples. Subjects of the JH
Center samples were deliberately selected for a pilot study
from individuals with less well-controlled diabetes and
severe hyperglycemia.
O-GlcNAc has been recognized as a stress responsive
modiﬁcation in many studies and O-GlcNAcylation has a
biphasic modal effect on cellular survival mechanisms
(for a review, ref. 26). O-GlcNAcylation modulates the
function of proteins upon stress—such as increased
stability, differential targeting, and activity changes—by
increasing global O-GlcNAcylation. Once cells are sta-
bilized, O-GlcNAcylation levels recover to the normal
range. This phenomenon may explain our observation in
pre-diabetic and diabetic erythrocytes. We speculate
that increased expression of O-GlcNAcase is an adapta-
tive response to hyperglycemia-induced hyper-O-Glc-
NAcylation. Increased O-GlcNAcase may remove excess
O-GlcNAcylation on proteins to stabilize and maintain the
function of erythrocytes. Additionally, the observation that
OGT expression levels did not change suggests that the
cells are trying not to over-O-GlcNAcylate proteins under
chronic hyperglycemia (Fig. 2). However, it remains un-
clear whether the OGT enzymatic activity or substrate
targeting in erythrocytes could be disturbed due to hyper-
glycemia. The concentration of UDP-GlcNAc, the donor of
O-GlcNAc, was not determined in this study because the
long-term storage of samples would result in the degrada-
tion of UDP-GlcNAc at unpredictable rates. In the search
for a new early diagnostic method to screen for diabetes,
these data suggest that analysis of O-GlcNAcase protein
levels could be a potential candidate. Protein expression
levels of O-GlcNAcase showed signiﬁcant increases in
pre-diabetes and diabetes (Fig. 3). It is important to note
that changes in A1C levels were not sensitive enough to
distinguish normal and pre-diabetic samples, however,
O-GlcNAcase showed more signiﬁcant distinction between
normal and pre-diabetic samples. This suggests that O-
GlcNAcase adapts to cellular stress at an earlier stage of
disease progression. Erythrocytes do not synthesize new
proteins once they are mature. Thus we presume that this
adaptation occurs during hematopoiesis in bone marrow
and continues until the reticulocytes complete their differ-
entiation. This pilot study suggests avenues for further
research. The correlation between hyperglycemia and the
measured O-GlcNAc parameters needs further deﬁnition.
The time kinetics over which changes in these parameters
occur—its relationship to A1C and metabolic side—needs
elucidation. Only a much larger clinical trial will determine
if increased O-GlcNAcylation has enough sensitivity and
speciﬁcity to have value as a diagnostic for pre-diabetes.
Nonetheless these pilot studies encourage further
investigation.
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